The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Immunotherapy for lung cancer
Open accessAbstract
Treatment of lung cancer remains a challenge, and lung cancer is still the leading cause of cancer‐related mortality. Immunotherapy has previously failed in lung cancer but has recently emerged as a very effective new therapy, and there is now growing worldwide enthusiasm in cancer immunotherapy. We summarize why immune checkpoint blockade therapies have generated efficacious and durable responses in clinical trials and why this has reignited interest in this field. Cancer vaccines have also been explored in the past with marginal success. Identification of optimal candidate neoantigens may improve cancer vaccine efficacy and may pave the way to personalized immunotherapy, alone or in combination with other immunotherapy such as immune checkpoint blockade. Understanding the steps in immune recognition and eradication of cancer cells is vital to understanding why previous immunotherapies failed and how current therapies can be used optimally. We hold an optimistic view for the future prospect in lung cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,002
B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells
Tseng, S.-Y., Otsuji, M., Gorski, K., Huang, X., Slansky, J. E., Pai, S. I., Shalabi, A., Shin, T., Pardoll, D. M., & Tsuchiya, H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.839 · Cited by 872
Exploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 810
Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591
Mu, C.-Y., Huang, J.-A., Chen, Y., Chen, C., & Zhang, X.-G. (2011) · Medical Oncology · doi:10.1007/s12032-010-9515-2 · Cited by 577
Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4802 · Cited by 535
Steinhagen, F., Kinjo, T., Bode, C., & Klinman, D. M. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.08.002 · Cited by 501
Lee, C. K., Brown, C., Gralla, R. J., Hirsh, V., Thongprasert, S., Tsai, C.-M., Tan, E. H., Ho, J. C.-M., Chu, D. T., Zaatar, A., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt072 · Cited by 501
Carbognin, L., Pilotto, S., Milella, M., Vaccaro, V., Brunelli, M., Caliò, A., Cuppone, F., Sperduti, I., Giannarelli, D., Chilosi, M., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0130142 · Cited by 447
Peart, W. S., Andrews, T. M., & Robertson, J. I. S. (1961) · The Lancet · doi:10.1016/s0140-6736(61)92247-4 · Cited by 405
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Meng, X., Huang, Z., Teng, F., Xing, L., & Yu, J. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.001 · Cited by 401
Molecular Cloning and Functional Expression of a Human Intestinal Lactoferrin Receptor
Suzuki, Y. A., Shin, K., & Lönnerdal, B. (2001) · Biochemistry · doi:10.1021/bi0155899 · Cited by 337
TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER
Kradin, R., Lazarus, D., Dubinett, S., Gifford, J., Grove, B., Kurnick, J., Preffer, F., Pinto, C., Davidson, E., Callahan, R., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91609-7 · Cited by 336
Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
Rozali, E. N., Hato, S. V., Robinson, B. W., Lake, R. A., & Lesterhuis, W. J. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/656340 · Cited by 328
Self-citationFong, L., & Small, E. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.8954 · Cited by 323
Cherfils-Vicini, J., Platonova, S., Gillard, M., Laurans, L., Validire, P., Caliandro, R., Magdeleinat, P., Mami-Chouaib, F., Dieu-Nosjean, M.-C., Fridman, W.-H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci36551 · Cited by 237
Nivolumab in NSCLC: latest evidence and clinical potential
Sundar, R., Cho, B.-C., Brahmer, J. R., & Soo, R. A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014567470 · Cited by 229
Quoix, E., Lena, H., Losonczy, G., Forget, F., Chouaid, C., Papai, Z., Gervais, R., Ottensmeier, C., Szczesna, A., Kazarnowicz, A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00483-0 · Cited by 211
Calabrò, L., Morra, A., Fonsatti, E., Cutaia, O., Fazio, C., Annesi, D., Lenoci, M., Amato, G., Danielli, R., Altomonte, M., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00092-2 · Cited by 206
Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
Brahmer, J. R., & Pardoll, D. M. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0078 · Cited by 190
Harnessing the Immune System for the Treatment of Non–Small-Cell Lung Cancer
Brahmer, J. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8703 · Cited by 154
Paz-Ares, L. G., Horn, L., Borghaei, H., Spigel, D. R., Steins, M. B., Ready, N., Chow, L. Q. M., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.18_suppl.lba109 · Cited by 146
Hirsh, V., Paz-Ares, L. G., Boyer, M. J., Rosell, R., Middleton, G., Eberhardt, W., Szczęsna, A., Reiterer, P., Saleh, M. N., Arrieta, O. G., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8971 · Cited by 141
Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy
Varadhachary, A., Wolf, J. S., Petrak, K., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20271 · Cited by 138
Manegold, C., van Zandwijk, N., Szczęsna, A., Zatloukal, P., Au, J. S. K., Błasińska-Morawiec, M., Serwatowski, P., Krzakowski, M. J., Jassem, J., Tan, E. H., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr030 · Cited by 130
Antonia, S. J., Gettinger, S. N., Chow, L. Q. M., Juergens, R. A., Borghaei, H., Shen, Y., Harbison, C. T., Chen, A. C., Ready, N., & Rizvi, N. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8023 · Cited by 125
Spira, A. I., Park, K., Mazières, J., Vansteenkiste, J., Rittmeyer, A., Ballinger, M. D., Waterkamp, D., Kowanetz, M., Mokatrin, A., & Fehrenbacher, L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8010 · Cited by 121
Chatterjee, S., Crozet, L., Damotte, D., Iribarren, K., Schramm, C., Alifano, M., Mansuet‐Lupo, A., Cherfils‐Vicini, J., Goc, J., Katsahian, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2698 · Cited by 113
Lung cancer: potential targets for immunotherapy
Tartour, É., & Zitvogel, L. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70159-0 · Cited by 94
Broomfield, S., der Most, R. G. V., Prosser, A., Mahendran, S., Tovey, M. G., Smyth, M. J., Robinson, B. W. S., & Currie, A. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803826 · Cited by 93
Self-citationGulley, J. L., Spigel, D. R., Kelly, K. L., Chandler, J. C., Rajan, A., Hassan, R., Wong, D. J. L., Leach, J., Edenfield, W. J., Wang, D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8034 · Cited by 91
Horn, L., Spigel, D. R., Gettinger, S. N., Antonia, S. J., Gordon, M. S., Herbst, R. S., Sequist, L. V. D., Chappey, C., Kowanetz, M., Sandler, A. B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8029 · Cited by 82
Brahmer, J. R., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8112 · Cited by 79
Smith, D. A. B., Conkling, P., Richards, D., Nemunaitis, J. J., Boyd, T. E., Mita, A. C., Bourdonnaye, G. D. L., Wages, D. S., & Bexon, A. S. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1547-6 · Cited by 75
Reprogramming the tumor microenvironment to enhance adoptive cellular therapy
Beavis, P. A., Slaney, C. Y., Kershaw, M. H., Gyorki, D. E., Neeson, P. J., & Darcy, P. K. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.11.003 · Cited by 75
Spigel, D. R., Chaft, J. E., Gettinger, S. N., Chao, B. H., Dirix, L. Y., Schmid, P., Chow, L. Q. M., Chappey, C., Kowanetz, M., Sandler, A. B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8028 · Cited by 73
The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer
Khong, A., Nelson, D. J., Nowak, A. K., Lake, R., & Robinson, B. W. S. (2012) · International Reviews of Immunology · doi:10.3109/08830185.2012.698338 · Cited by 71
Self-citationWeihrauch, M. R., Richly, H., von Bergwelt‐Baildon, M. S., Becker, H., Schmidt, M., Hacker, U. T., Shimabukuro‐Vornhagen, A., Holtick, U., Nokay, B., Schroff, M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.11.002 · Cited by 70
Patnaik, A., Socinski, M. A., Gubens, M. A., Gandhi, L., Stevenson, J. P., Bachman, R. D., Bourque, J., Ge, J. Y., Im, E., & Gadgeel, S. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8011 · Cited by 69
Nelson, D. J., Bundell, C. S., & Robinson, B. W. S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6123 · Cited by 63
Self-citationRamalingam, S. S., Crawford, J., Chang, A. Y., Manegold, C., Perez-Soler, R., Douillard, J.-Y., Thatcher, N., Barlési, F., Owonikoko, T. K., Wang, Y., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt371 · Cited by 58
Immunotherapy as a strategy for the treatment of non-small-cell lung cancer
Holt, G. E., Podack, E. R., & Raez, L. E. (2010) · Therapy · doi:10.2217/thy.10.84 · Cited by 57
Why has active immunotherapy not worked in lung cancer?
Thomas, A., & Giaccone, G. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv323 · Cited by 54
Genomic Approaches to Lung Cancer
Thomas, R. K., Weir, B. A., & Meyerson, M. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0098 · Cited by 54
Vansteenkiste, J., Cho, B. C., Vanakesa, T., Pas, T. M. D., Zielinski, M., Kim, M. S., Jassem, J., Yoshimura, M., Dahabreh, J., Nakayama, H., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu347.1 · Cited by 54
PD-L2 is predominantly expressed by Th2 cells
Lesterhuis, W. J., Steer, H. J., & Lake, R. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.09.014 · Cited by 47
Antonia, S. J., Goldberg, S. B., Balmanoukian, A. S., Sanborn, R. E., Steele, K. E., Narwal, R., Robbins, P. B., Gu, Y. L., Karakunnel, J. J., & Rizvi, N. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3014 · Cited by 47
Lactoferrin Inhibits Growth of Malignant Tumors of the Head and Neck
Wolf, J. S., Li, D., Taylor, R. J., et al. (2003) · ORL · doi:10.1159/000075220 · Cited by 38
Spadaro, M., Curcio, C., Varadhachary, A., Cavallo, F., Engelmayer, J., Blezinger, P., Pericle, F., & Forni, G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4080 · Cited by 36
Gettinger, S. N., Hellmann, M. D., Shepherd, F. A., Antonia, S. J., Brahmer, J. R., Chow, L. Q. M., Goldman, J. W., Juergens, R. A., Borghaei, H., Ready, N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8025 · Cited by 36
Kelly, K. L., Patel, M. R., Infante, J. R., Iannotti, N. O., Nikolinakos, P. G., Leach, J., Wang, D., Chandler, J. C., Jérusalem, G., Gurtler, J. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3044 · Cited by 35
Vaccine immunotherapy in lung cancer: Clinical experience and future directions
Freeman-Keller, M., Goldman, J. M., & Gray, J. E. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.004 · Cited by 34
Papadimitrakopoulou, V. A., Patnaik, A., Borghaei, H., Stevenson, J. P., Gandhi, L., Gubens, M. A., Yang, J. C., Sequist, L. V. D., Ge, J. Y., Bourque, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8031 · Cited by 34
Can the exome and the immunome converge on the design of efficient cancer vaccines?
Kroemer, G., & Zitvogel, L. (2012) · OncoImmunology · doi:10.4161/onci.20730 · Cited by 24
Restoration of defective cross-presentation in tumors by gemcitabine
McDonnell, A. M., Lesterhuis, W. J., Khong, A., Nowak, A. K., Lake, R., Currie, A. J., & Robinson, B. W. S. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1005501 · Cited by 21
Self-citationNarusawa, M., Inoue, H., Sakamoto, C., Matsumura, Y., Takahashi, A., Inoue, T., Watanabe, A., Miyamoto, S., Miura, Y., Hijikata, Y., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0143 · Cited by 17
Tatipalli, M., Song, X., Pak, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.e14010 · Cited by 2
Cited by
Wu, M., Huang, Q., Xie, Y., Wu, X., Ma, H., Zhang, Y., & Xia, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01242-2 · Cited by 456
Pyroptosis, metabolism, and tumor immune microenvironment
Du, T., Gao, J., Li, P., Wang, Y., Qi, Q., Liu, X., Li, J., Wang, C., & Du, L. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.492 · Cited by 324
Contribution of Angiogenesis to Inflammation and Cancer
Aguilar-Cazares, D., Chavez-Dominguez, R., Carlos-Reyes, A., Lopez-Camarillo, C., Hernadez de la Cruz, O. N., & Lopez-Gonzalez, J. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01399 · Cited by 317
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Tang, S., Qin, C., Hu, H., Liu, T., He, Y., Guo, H., Yan, H., Zhang, J., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11030320 · Cited by 256
Design strategies and applications of cyanine dyes in phototherapy
Yuan, J., Yang, H., Huang, W., Liu, S., Zhang, H., Zhang, X., & Peng, X. (2025) · Chemical Society Reviews · doi:10.1039/d3cs00585b · Cited by 143
Metadata
- Authors
- Steven, A., Fisher, S. A., & Robinson, B. W.
- Venue
- Respirology
- Publisher
- Wiley
- Published
- 2016-04-21
- Volume
- 21
- Issue
- 5
- Pages
- 821-833
- ISSN
- 1323-7799 (ISSN-L)
- 1440-1843
- OpenAlex
- W2342642001
- Cited by
- 338
- References
- 81
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.